Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Pregnancy not linked to increased myasthenia gravis flare-up risk

13

May 2026

Pregnancy not linked to increased myasthenia gravis flare-up risk

For female participants with myasthenia gravis, pregnancy is not associated with an increased risk of serious flare-ups of the disease, or new or worsening symptoms, according to a study published May 13, 2026, in Neurology, the medical journal of the American Academy of Neurology.

Why experts say PCOS needs a new name

13

May 2026

Why experts say PCOS needs a new name

A Lancet Health Policy paper reports an international consensus process that selected polyendocrine metabolic ovarian syndrome (PMOS) as the new name for polycystic ovary syndrome (PCOS). The change aims to shift the focus away from ovarian cysts and better reflect the condition’s endocrine, metabolic, and ovarian features.

Study identifies genetic pathways linking cannabis use and psychosis

13

May 2026

Study identifies genetic pathways linking cannabis use and psychosis

New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London has highlighted the distinct and shared molecular pathways linking cannabis use disorder (CUD) and psychosis, offering the potential for identifying those at risk, as well as targeted interventions for cannabis related psychosis.

Global health progress reversing in several critical areas, WHO warns

13

May 2026

Global health progress reversing in several critical areas, WHO warns

While there have been meaningful improvements in global health over the past decade, with millions benefiting from better prevention, treatment and access to essential services, persistent and emerging challenges mean that the world remains off track to achieve any of the health-related Sustainable Development Goals (SDGs) by 2030.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.